Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: Ex vivo and in vitro studies

Journal of Pathology

Volumn 215, Issue 2, 2008, Pages 184-194

  Bryan, R T ^a,b   Atherfold, P A ^c   Yeo, Y ^d   Jones, L J ^e   Harrison, R F ^f   Wallace, D M A ^b   Jankowski, J A ^c,f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Bladder; Cadherin; Catenin; Cell culture; In vitro models; Neoplasia

Indexed keywords

BETA CATENIN; CADHERIN; P CADHERIN; UVOMORULIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; DISEASE SEVERITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOG RANK TEST; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE CULTURE; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

BETA CATENIN; BLOTTING, WESTERN; CADHERINS; CARCINOMA, TRANSITIONAL CELL; CATENINS; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 44649103239     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2346     Document Type: Article

References (47)

1. Office for National Statistics. Bladder cancer (ICD10 C67) incidence and mortality by country of UK and region of England; latest year available; May 2001; www.statistics.gov.uk.
2. Morrison AS, Proppe KH, Verhoek WG, Aoki K, Leek I, Ohno Y, et al. Histologic features of bladder cancer in Boston, USA, Manchester, UK, and Nagoya, Japan. Int J Cancer 1982;30:701-705.
3. Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 1997;14:98-108.
4. Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol 2000;299:551-572.
5. Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K, et al. A truncated β-catenin disrupts the interaction between E-cadherin and α-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 1994;54:6282-6287.
6. Knudsen KA, Wheelock MJ. Plakoglobin, or an 83 kD homologue distinct from β-catenin, interacts with E-cadherin and N-cadherin. J Cell Biol 1992;118:671-679.
7. Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J Cell Biol 1994;127:2061-2069.
8. Aghib DF, McCrea PD. The E-cadherin complex contains the src substrate p120. Exp Cell Res 1995;218:359-369.
9. Adams CL, Nelson WJ, Smith SJ. Quantitative analysis of cadherin-catenin-actin reorganization during development of cell-cell adhesion. J Cell Biol 1996;135:1899-1911.
10. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 1993;53:3241-3245.
11. Syrigos KN, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J, et al. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer 1995;64:367-370.
12. Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, et al. Prognostic value of cadherin-associated molecules (α-, β- and γ-catenins and p120cas) in bladder tumors. Cancer Res 1996;56:4154-4158.
13. Mialhe A, Louis J, Montlevier S, Peoch M, Pasquier D, Bosson JL, et al. Expression of E-cadherin and α-, β- and γ-catenins in human bladder carcinomas: are they good prognostic factors? Invas Metast 1997;17:124-137.
14. Giroldi LA, Bringuier PP, Shimazui T, Jansen K, Schalken JA. Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. Int J Cancer 1999;82:70-76.
15. Garcia del Muro X, Torregrosa A, Munoz J, Castellsague X, Condom E, Vigues F, et al. Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. Eur J Cancer 2000;36:357-362.
16. Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P, et al. Prognostic value of E-cadherin, β-catenin, p120ctn in patients with transitional cell bladder cancer. Anticancer Res 2000;20:4571-4578.
17. Rieger-Christ KM, Cain JW, Braasch JW, Dugan JM, Silverman ML, Bouyonnes B, et al. Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol 2001;32:18-23.
18. Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M. Dominant role of E-cadherin in the progression of bladder cancer. J Urol 1999;161:692-698.
19. Stoehr R, Krieg RC, Knuechel R, Hofstaedter F, Pilarsky C, Zaak D, et al. No evidence for involvement of β-catenin and APC in urothelial carcinomas. Int J Oncol 2002;20:905-911.
20. Mostofi FK, Sobin LH, Tosoni I. Histological typing of urinary bladder tumours. International Classification of Tumours, No. 19. World Health Organization: Geneva, 1973.
21. Perry I, Tselepis C, Hoyland J, Iqbal TH, Sanders DSA, Cooper BT, et al. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab Invest 1999;79:1489-1499.
22. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, et al. Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071-6081.
23. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia- adenocarcinoma sequence: correlation with disease progression and dedifferentaition. Am J Pathol 1998;152:135-144.
24. Jankowski JA, Bedford FK, Boulton RA, Cruickshank N, Hall C, Elder J, et al. Alterations in classical cadherins associated with progression in ulcerative and Crohn's colitis. Lab Invest 1998;78:1155-1167.
25. Bryan RT, Nicholls J, Harrison RF, Jankowski JA, Wallace DMA. The role of β-catenin signalling in the malignant potential of cystitis glandularis. J Urol 2003;170:1892-1896.
26. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-1790.
27. Medical Research Council. Human Tissue and Biological Samples for Use in Research. Operational and Ethical Guidelines. MRC Ethics Series. MRC: London, 2001.
28. Perry I, Hardy R, Jones T, Jankowski J. A colorectal cell line with alterations in E-cadherin and epithelial biology may be an in vitro model of colitis. Mol Pathol 1999;52:231-242.
29. Harris JC, Clarke PA, Awan A, Jankowski J, Watson SA. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004;64:1915-1919.
30. Hardy RG, Brown RM, Miller SJ, Tselepis C, Morton DG, Jankowski JA, et al. Transient P-cadherin expression in radiation proctitis; a model of mucosal injury and repair. J Pathol 2002;197:194-200.
31. Hardy RG, Tselepis C, Hoyland J, Wallis Y, Pretlow TP, Talbot I, et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut 2002;50:513-519.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
33. Liu BC, Droller MJ. Biochemistry of human bladder tumor invasion. Scand J Urol Nephrol Suppl 1991;138:145-151.
34. Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 1977;58:1743-1751.
35. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, et al. Tissue cell lines. Cancer Res 1986;46:3630-3636.
36. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-185.
37. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-119.
38. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-1252.
39. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999;86:1263-1272.
40. Paredes J, Stove C, Stove V, Milanezi F, van Marck V, Derycke L, et al. P-cadherin is upregulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res 2004;64:8309- 8317.
41. van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y, et al. P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res 2005;65:8774-8783.
42. Bauer R, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, et al. Prognostic relevance of P-cadherin expression in melanocyte skin tumours analysed by high throughput tissue microarrays. J Clin Pathol 2006;59:699-705.
43. Bauer R, Hein R, Bosserhof AK. A secreted form of P-cadherin is expressed in malignant melanoma. Exp Cell Res 2005;305:418-426.
44. Bauer R, Bosserhof AK. Functional implication of truncated P-cadherin expression in malignant melanoma. Exp Mol Pathol 2006;81:224-230.
45. Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumours. Clin Cancer Res 2006;12:2780-2787.
46. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13:7003-7011.
47. Pyo SW, Hashimoto M, Kim YS, Kim CH, Lee SH, Johnson KR, et al. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome. J Craniomaxillofac Surg 2007;35:1-9.